Eliem Therapeutics appoints Brett Kaplan as COO with equity grants

Climb Bio, Inc.

Brett Kaplan, M.D., appointed Chief Operating Officer effective August 26, 2024.
Base salary of $500,000/year; eligible for annual bonus up to 45% of base salary.
Granted option to purchase 465,000 shares and 77,500 RSUs under 2021 Equity Incentive Plan.
Option vests 25% at one year then monthly over 3 years; RSUs vest 25% annually over 4 years.
Severance: 9 months salary (non-CIC) or 12 months plus target bonus (CIC), plus COBRA and equity acceleration.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brett Kaplan, M.D.

Chief Operating Officer

CLYM · Climb Bio, Inc.

Effective: 2024-08-26
Filed: August 26, 2024, 7:59 PM ET

On August 26, 2024, Eliem Therapeutics, Inc. (the “Company”) announced that its board of directors (the “Board”) had appointed Brett Kaplan, M.D., as Chief Operating Officer of the Company, effective August 26, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brett Kaplan, M.D. was appointed as Chief Operating Officer at Climb Bio, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On August 26, 2024, Eliem Therapeutics, Inc. (the “Company”) announced that its board of directors (the “Board”) had appointed Brett Kaplan, M.D., as Chief Operating Officer of the Company, effective August 26, 2024

View on SEC.gov

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-206655

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.